CD30 is a member of the tumor necrosis factor receptor superfamily. It is characteristically expressed in certain hematopoietic malignancies, including anaplastic large cell lymphoma and Hodgkin ...

CD30/Ki-1-positive lymphoproliferative disorders of the skin--clinicopathologic correlation and statistical analysis of 86 cases: a multicentric study from the European Organization for Research and ...

Cells of certain blood cancers such as Hodgkin’s lymphoma carry the protein CD30 on their surface. The molecule is not only an indicator of a few cancers of the immune system but also increases the ...

Researchers from the Sant Pau Research Institute (IR Sant Pau), in collaboration with Sant Pau Hospital and the Josep Carreras Leukaemia Research Institute, have developed an innovative CAR-T cell ...

A recent study explored the efficacy of brentuximab vedotin (BV) in patients with high-CD30–expressing non-Hodgkin lymphoma (NHL) to determine who is most likely to benefit. A recent study explored ...

Use of octreotide in the symptomatic management of diarrhea induced by graft-versus-host disease in patients with hematologic malignancies. CD30 ligand (CD30L), which is expressed on resting B and ...

Please provide your email address to receive an email when new articles are posted on . Since the discovery of the CD30 molecule in 1982, progress has been made in the treatment and survival outcomes ...

The results of a preclinical study have identified a biological mechanism that explains why some patients don’t respond to immune checkpoint blockade (ICB) therapy for solid cancer tumors. The study, ...

Hodgkin's lymphoma and anaplastic large-cell lymphoma are the two most common tumors expressing CD30. Previous attempts to target the CD30 antigen with monoclonal-based therapies have shown minimal ...